Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + SBRT in Liver Metastatic Colorectal Cancer
NCT02837263Phase 1Completed
- Sponsor
- University of Wisconsin–Madison
- Start
- Aug 2016
- Primary completion
- Nov 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pembrolizumab in colorectal cancer (CRC), sponsored by University of Wisconsin–Madison. Primary endpoint: Recurrence Rate at 1 Year. Started Aug 2016; status: completed.
02
Drugs
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02837263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02837263.